![Frontiers | Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases Frontiers | Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases](https://www.frontiersin.org/files/Articles/405758/fmicb-09-03158-HTML/image_m/fmicb-09-03158-g001.jpg)
Frontiers | Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases
![One Chain Immunotherapeutics on Twitter: "Great news! 🙌 #OneChain has received 2,5 million euros from the @EUeic to bring to the bedside a CAR-T therapy for T-ALL patients! Let us tell you One Chain Immunotherapeutics on Twitter: "Great news! 🙌 #OneChain has received 2,5 million euros from the @EUeic to bring to the bedside a CAR-T therapy for T-ALL patients! Let us tell you](https://pbs.twimg.com/media/Fq2bAFxX0AEoptZ.jpg)
One Chain Immunotherapeutics on Twitter: "Great news! 🙌 #OneChain has received 2,5 million euros from the @EUeic to bring to the bedside a CAR-T therapy for T-ALL patients! Let us tell you
![Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy | Journal of Hematology & Oncology | Full Text Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-020-00862-w/MediaObjects/13045_2020_862_Fig1_HTML.png)
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy | Journal of Hematology & Oncology | Full Text
![Invivo Ventures, CDTI-Innvierte y la Fundación Josep Carreras cierran una ronda de financiación de 3.050.000€ en OneChain Immunotherapeutics - Capital-Riesgo.es Invivo Ventures, CDTI-Innvierte y la Fundación Josep Carreras cierran una ronda de financiación de 3.050.000€ en OneChain Immunotherapeutics - Capital-Riesgo.es](http://capital-riesgo.es/files/media/image/articles/2020/07/original/7392onechain_invivo.jpg)
Invivo Ventures, CDTI-Innvierte y la Fundación Josep Carreras cierran una ronda de financiación de 3.050.000€ en OneChain Immunotherapeutics - Capital-Riesgo.es
OneChain Immunotherapeutics S.L (OCI)* is a new and dynamic spin-off company based on Barcelona dedicated to advance the pre-cli
OneChain Immunotherapeutics S.L (OCI) is a clinical stage spin-off company from Fundación Josep Carreras invested also by Inviv
![A guide to cancer immunotherapy: from T cell basic science to clinical practice | Nature Reviews Immunology A guide to cancer immunotherapy: from T cell basic science to clinical practice | Nature Reviews Immunology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41577-020-0306-5/MediaObjects/41577_2020_306_Fig1_HTML.png)